Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVE0657 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Level 1 | EXPERIMENTAL | - |
| Dose Level 2 | EXPERIMENTAL | - |
| Dose Level 3 | EXPERIMENTAL | - |
| Dose Level 4 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | 12 subjects: 3 subjects per dose level |
| Name | Type | Description |
|---|---|---|
| AVE0657 | DRUG | capsules once a day at bedtime |
| placebo | DRUG | capsules once a day at bedtime |
Inclusion Criteria: * Subjects diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome based on International Classification of Sleep Disorders Exclusion Criteria: * Subjects having been treated by Continuous Positive Airway Pressure, oral appliance during 4-weeks prior to randomization * Chroni...
AVE0657 is an investigational small molecule being developed for the treatment of obstructive sleep apnea. It is currently in clinical development and has not been approved by regulatory authorities.
AVE0657 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY.
AVE0657 is in Phase 2 clinical development. It remains investigational and has not received regulatory approval.
AVE0657 has one completed Phase 2 clinical trial, identified as NCT00614250, which evaluated its effect on obstructive sleep apnea in 38 participants across France, Germany, and Spain.
Yes, AVE0657 is a small molecule therapeutic agent. It is being studied for its potential role in treating obstructive sleep apnea.